Dried Blood Spot Testing: How DBS Technology Is Reshaping Diagnostics

The shift from venepuncture to microsampling

For most of the history of laboratory diagnostics, testing blood has meant sitting in a clinic, rolling up a sleeve, and watching a phlebotomist fill one or more vacuum tubes. That model works well when the patient is already in the building, the lab is down the corridor, and refrigerated transport is available within hours. It works less well when the goal is population-wide screening, remote patient monitoring, at-home consumer testing, or decentralised clinical trials.

Dried blood spot (DBS) testing eliminates most of those constraints. The patient collects a few drops of capillary blood from a finger prick onto a specialised filter paper card. The sample dries in minutes, stabilises at room temperature, and can be posted to a laboratory anywhere in the world as standard mail. On arrival, the lab punches a small disc from the card, extracts the analytes, and measures them with the same high-resolution instruments used for conventional samples.

The global DBS testing market was valued at approximately USD 436 million in 2024 and is projected to reach USD 830 million by 2033, growing at a compound annual rate of 7.4%. That growth is being driven not by a single application but by a convergence of demand from multiple sectors: preventive health programmes, wellness brands, pharmaceutical research, newborn screening, and clinical care.

How DBS testing actually works

Understanding the technology behind DBS is important for any organisation evaluating it as part of a product or service. The process involves four stages: collection, transport, extraction, and analysis.

Collection. A spring-loaded lancet creates a small puncture on the fingertip. The blood is applied directly to pre-printed circles on a cellulose or polymer-based filter card. Each spot absorbs approximately 20–50 µL of whole blood — roughly one-tenth of what a single venous tube requires. No phlebotomist is needed, and the patient (or study participant, or consumer) can collect the sample at home with minimal instruction.

Transport. Once dry — typically within two to three hours — the card is placed in a foil-lined envelope with desiccant and posted to the laboratory. Because the sample is dried and classified as non-infectious, it does not require biohazard packaging, cold-chain logistics, or expedited shipping. This is the single largest cost and infrastructure advantage DBS holds over venous collection, and it is the reason the technology scales to populations that venepuncture cannot easily reach.

Extraction. In the laboratory, a precision puncher removes a consistent disc (typically 3–6 mm in diameter) from each blood spot. The disc is immersed in an extraction solvent tailored to the target analytes — organic solvents for lipophilic compounds, aqueous buffers for water-soluble metabolites. Internal standards are added at this stage to correct for analytical variation.

Analysis. The extract is injected into a liquid chromatography–tandem mass spectrometry (LC-MS/MS) or gas chromatography (GC-FID) system. These instruments separate, identify, and quantify individual molecules with high specificity and sensitivity, producing results that are directly comparable to those obtained from serum or plasma — provided the method has been properly validated. Method validation is not optional; it is the difference between a research curiosity and a clinically reliable result.

What DBS can measure

One of the most common misconceptions about DBS is that it is limited to newborn screening. While newborn screening programmes were the earliest large-scale application — and still represent the largest single segment of the DBS market — the technology has expanded dramatically. Modern LC-MS/MS methods can quantify a wide range of clinical biomarkers from a dried blood spot, including:

Vitamins and micronutrients: 25-OH vitamin D, retinol (vitamin A), and alpha-tocopherol (vitamin E). These are among the most commonly tested analytes in preventive health and nutritional monitoring.

Fatty acids: The Omega-3 Index (EPA + DHA as a percentage of total erythrocyte fatty acids) is one of the most widely validated DBS biomarkers, with applications in cardiovascular risk assessment, prenatal health, and supplementation monitoring.

Metabolic markers: Homocysteine, HbA1c, amino acid profiles, and CoQ10 can all be quantified from DBS, enabling metabolic health assessment without a clinic visit.

Cellular health biomarkers: Glutathione (reduced and oxidised forms) and NAD+ are increasingly requested for longevity and functional medicine applications. Measuring these from DBS makes longitudinal tracking practical for the first time.

Rare disease screening: LPC-VLCFA quantification enables newborn screening for X-linked adrenoleukodystrophy (X-ALD), a devastating peroxisomal disorder where early detection can prevent irreversible neurological damage.

The breadth of analytes available from DBS is limited primarily by two factors: the sensitivity of the analytical instrument and the stability of the analyte on filter paper. Both continue to improve as LC-MS/MS platforms become more sensitive and sample collection card chemistry evolves.

Why DBS matters for healthcare professionals

For clinicians and healthcare providers, DBS removes one of the most persistent barriers to biomarker testing: the need for the patient to be physically present in a clinical setting with venepuncture capability. This has direct implications for several clinical scenarios.

Patients managing chronic conditions — diabetes (HbA1c), cardiovascular risk (Omega-3 Index, homocysteine), or metabolic disorders — can monitor their biomarkers at home and share results with their care team remotely. This reduces missed appointments, increases testing compliance, and provides longitudinal data that a single clinic visit cannot.

In functional and integrative medicine, where practitioners often work with patients who travel significant distances, DBS enables follow-up testing without requiring return visits. Markers such as NAD+, glutathione, and amino acid profiles, which are central to personalised health optimisation, become practical to track over time.

Paediatric populations benefit particularly. The reduced sample volume and minimal invasiveness of a finger prick make DBS far more tolerable for children and infants than venepuncture, improving both compliance and parental willingness to test.

Why DBS matters for researchers

Clinical and academic researchers face a recurring challenge: recruiting and retaining study participants, especially in geographically distributed or remote populations. DBS dramatically lowers the burden of participation. Instead of attending a clinic for each blood draw, participants collect their own samples at home and mail them in.

This capability is particularly valuable in decentralised clinical trials, epidemiological studies, and longitudinal cohort research where repeated sampling is needed over months or years. The ambient-temperature stability of DBS cards also simplifies logistics in regions without reliable cold-chain infrastructure — a significant advantage for studies conducted across tropical climates, rural areas, or resource-limited settings.

From an analytical standpoint, researchers benefit from the smaller sample volume. When multiple biomarkers can be measured from a single card, participant burden decreases and the dataset becomes richer without additional blood draws.

Why DBS matters for health brands and distributors

The at-home health testing market has grown rapidly, and DBS is the technology that makes most of these products possible. Supplement companies, wellness brands, and health tech platforms are increasingly offering diagnostic testing as a companion to their products — not just to differentiate their brand, but to demonstrate measurable outcomes.

A supplement company selling omega-3 capsules, for example, can offer a pre- and post-supplementation Omega-3 Index test to show customers whether the product is actually raising their levels. A longevity brand can pair its NAD+ precursor with an NAD+ blood test. A prenatal nutrition company can include a DHA test in its subscription box. In each case, the laboratory partner handles the analytical work while the brand owns the customer relationship.

For distributors and resellers, DBS-based test kits are straightforward to stock, ship, and sell. The kits require no refrigeration, have long shelf lives, and can be distributed globally without special handling requirements. White-label programmes allow the test to carry the partner's branding while the laboratory provides the analysis, reporting, and quality assurance behind the scenes.

What to look for in a DBS laboratory partner

Not all DBS laboratories are equal, and the differences matter. Whether you are a healthcare provider, a researcher, or a brand launching a test kit, there are several factors to evaluate when selecting a laboratory partner.

Validated analyte menu. A laboratory should be able to demonstrate that each analyte has been specifically validated from dried blood spots — not simply adapted from a serum method. Validation should include accuracy, precision, linearity, and stability studies, with correlation data against venous reference methods.

Analytical platform. LC-MS/MS and GC-FID are the gold-standard analytical techniques for DBS biomarker quantification. Immunoassay-based methods may be cheaper but often lack the specificity and multiplexing capability that mass spectrometry provides.

Accreditation. Look for ISO 15189 (medical laboratories) or equivalent accreditation. This is not a formality — it reflects that the laboratory operates under a quality management system with external auditing, proficiency testing, and documented procedures.

Logistics and turnaround. A DBS programme is only as fast as its slowest step. The laboratory should have established postal workflows, clear sample tracking, and consistent turnaround times (typically 2–5 working days from sample receipt for most analytes).

White-label and integration capability. If you are building a branded product, ask about white-label reporting, API integration for result delivery, and the flexibility to customise the test panel to your clinical or commercial needs. A laboratory that specialises in DBS will have these capabilities built in, not bolted on.

Breadth of expertise. Laboratories that offer DBS alongside a broad analytical portfolio — metabolomics, endocrinology, toxicology, rare disease screening — are better positioned to support evolving test menus and cross-disciplinary research. A specialist DBS lab is rare; one that combines DBS expertise with deep mass spectrometry capability across multiple clinical domains is rarer still.

The state of the DBS landscape

Despite the technology's advantages, the number of laboratories that truly specialise in DBS-based biomarker quantification remains small. Most large reference laboratories offer a handful of DBS assays — typically newborn screening panels — but few have built their entire analytical infrastructure around dried blood spot collection.

The reasons are partly historical and partly technical. DBS method development requires different extraction chemistry, different calibration strategies, and different quality control procedures than conventional serum analysis. It demands investment in sample handling workflows designed specifically for filter paper cards rather than tubes. And it requires validation work for every analyte, on every card type, under every relevant storage condition.

This creates both a challenge and an opportunity. For organisations looking to integrate DBS into their offering — whether in clinical care, research, or consumer health — the scarcity of specialist laboratories means that choosing the right partner is critical. The right partner will not only analyse the sample accurately but will also understand the operational realities of running a DBS programme: kit design, postal logistics, sample adequacy checks, and result reporting at scale.

Where the technology is heading

Several trends are converging to accelerate DBS adoption. Advances in LC-MS/MS sensitivity continue to lower the detection limits achievable from small-volume samples, expanding the range of analytes that can be reliably measured from a single blood spot. Volumetric absorptive microsampling (VAMS) devices, which collect a fixed volume of blood regardless of haematocrit, are complementing traditional filter paper cards in applications where volumetric precision is critical.

On the demand side, the growth of personalised nutrition, functional medicine, and longevity health is creating a market for repeated biomarker testing that is impractical with venepuncture alone. Regulatory agencies in multiple jurisdictions are beginning to accept DBS-derived data in drug development submissions, further legitimising the technology for pharmaceutical applications.

Perhaps most significantly, the COVID-19 pandemic demonstrated at scale that patients can successfully collect their own blood samples at home when given clear instructions and appropriate tools. That behavioural shift has not reversed. The expectation of convenient, decentralised health testing is now embedded in how both consumers and healthcare systems think about diagnostics.